Related Experiment Video
Updated: Apr 18, 2026
11:49
Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery
Published on: April 3, 2026
326
Video endoscopic inguinal lymphadenectomy for lymph node metastasis from solid tumors.
A Sommariva1, S Pasquali2, C R Rossi3
1Melanoma and Sarcoma Unit, IOV- Veneto Institute of Oncology, IOV-IRCCS, Padova, Italy.
Summary
Video endoscopic inguinal lymphadenectomy (VEIL) shows promise for reducing complications compared to traditional open surgery. Further trials are needed to confirm its oncological outcomes and safety for routine use in treating inguinal lymph node metastasis.
Area of Science:
- Surgical Oncology
- Minimally Invasive Surgery
- Urologic Oncology
Background:
- Inguinal lymphadenectomy (IL) is standard for managing inguinal lymph node (LN) metastases.
- Video endoscopic inguinal lymphadenectomy (VEIL) is an emerging technique aiming to reduce complications.
- The safety and efficacy of VEIL require further investigation.
Purpose of the Study:
- To systematically review the literature on video endoscopic inguinal lymphadenectomy (VEIL).
- To assess the safety, feasibility, and outcomes of VEIL compared to traditional IL.
- To evaluate post-operative complications, operative time, and recurrence rates associated with VEIL.
Main Methods:
- Systematic literature review of studies reporting on VEIL procedures.
- Extraction and analysis of patient characteristics, operative data, and post-operative outcomes.
- Comparison of VEIL outcomes with historical data from open inguinal lymphadenectomy.
Main Results:
- Ten series involving 236 procedures in 168 patients were reviewed.
- Wound-related complications and seroma rates were between 0-13.3% and 4-38.4%, respectively.
- Local recurrence rates were up to 6.6%, with comparable lymph node yields to open dissection.
Conclusions:
- VEIL is safe and feasible for surgeons experienced in laparoscopy and groin anatomy.
- Post-operative morbidity, particularly wound-related issues, appears lower with VEIL.
- Further randomized controlled trials are necessary to validate VEIL's oncological outcomes and reduced morbidity for routine practice.
